Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study
Background and objective Real-world evidence on persistence of interleukin-17 inhibitors (IL-17i) as a drug class among Japanese patients with psoriasis is lacking. Hence, we aimed to describe persistence rates of IL-17is among patients with psoriasis including psoriasis vulgaris (PsO), psoriatic ar...
Saved in:
Main Authors: | Chaochen Wang (Author), Hitoe Torisu-Itakura (Author), Takao Hanada (Author), Takashi Matsuo (Author), Zhihong Cai (Author), Satoshi Osaga (Author), Toshihiko Aranishi (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
by: Masaru Honma, et al.
Published: (2020) -
Targeting of interleukin-17 in the treatment of psoriasis
by: Lønnberg AS, et al.
Published: (2014) -
Increased Levels of Interleukin-17A Exosomes in Psoriasis
by: Claire Jacquin-Porretaz, et al.
Published: (2019) -
Interleukin-17 levels in patients with psoriasis with or without metabolic syndrome
by: Hanan Morsy, et al.
Published: (2019) -
Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
by: Julia S. Kovaleva, et al.
Published: (2024)